trending Market Intelligence /marketintelligence/en/news-insights/trending/adlkpnvyhyrtmtlopaepha2 content esgSubNav
In This List

CASI Pharmaceuticals raises $50M via sale of shares

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


CASI Pharmaceuticals raises $50M via sale of shares

CASI Pharmaceuticals Inc. raised $50 million to prepare for the commercialization of its first product in China.

Rockville, Md.-based CASI Pharmaceuticals sold 15,432,091 shares of the company at $3.24 each, complete with warrants to purchase up to an additional 6,172,832 stock at $3.69 apiece.

ETP Global Fund LP; IDG-Accel China Growth Fund III; and Robert Duggan, former CEO and chairman of Pharmacyclics Inc., led the funding.

The company's Evomela, Marqibo and Zevalin products are in various regulatory stages for market approval in China.